Market Place
Sourcing Support
All News #Library
Biotech
Phanes Therapeutics Expands Spevatamig in Biliary tract Cancer
07 Apr 2026 //
PR NEWSWIRE
Phanes Therapeutics To Showcase 3 Clinical Posters At AACR 2026
18 Mar 2026 //
PR NEWSWIRE
Phanes Therapeutics Reports Spevatamig (PT886) Phase 2 Success
10 Jan 2026 //
PR NEWSWIRE
Phanes Therapeutics To Unveil Spevatamig (PT886) Combo Study
09 Dec 2025 //
PR NEWSWIRE
Phanes Therapeutics Doses First BTC Patient in Spevatamig Study
08 Sep 2025 //
PR NEWSWIRE
Phanes Therapeutics Doses First Patient in PT199 Clinical Study
27 May 2025 //
PR NEWSWIRE
Phanes Therapeutics Doses First Patient in Peluntamig Study
05 May 2025 //
PR NEWSWIRE
Phanes 1st Patient Dosed in Peluntamig Study with Chemotherapy
19 Feb 2025 //
PR NEWSWIRE
FDA Grants Fast Track To Phanes’ PT217 For NEPC
04 Dec 2024 //
PR NEWSWIRE
Veravas with Phanes Biotech on Tau Pathology Test for Alzheimer`s
07 Nov 2024 //
BUSINESSWIRE
Phanes Therapeutics Doses First Patient In PT886 Combo Therapy Study
09 Sep 2024 //
PR NEWSWIRE
Phanes Receives FDA Orphan Drug Designation For Neuroendocrine Carcinoma
16 Aug 2024 //
PR NEWSWIRE
Phanes Therapeutics, Inc.: Clinical Supply Agreement with Roche for PT217
08 May 2024 //
PR NEWSWIRE
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration with Merck
16 Oct 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.